EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Impact of RA treatment strategies on lipids and vascular inflammation in rheumatoid arthritis: a secondary analysis of the TARGET randomized active comparator trial

Katherine P Liao, Pamela Rist, Jon Giles, Leah Santacroce, Margery A Connelly, Robert J Glynn, Paul Ridker, Ahmed Tawakol, Joan Bathon, Daniel H Solomon

Arthritis Research & Therapy · 2024

DOI: 10.1186/s13075-024-03352-3 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Arthritis Research & Therapy, 2024. Verfasst von Katherine P Liao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, 60 Fenwood Rd, Boston, MA, 02115, USA. kliao@bwh.harvard.edu. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Antirheumatic Agents, Hydroxychloroquine, Lipids. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIAMS NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Treatments for rheumatoid arthritis (RA) are associated with complex changes in lipids and lipoproteins that may impact cardiovascular (CV) risk. The objective of this study was to examine lipid and lipoprotein changes associated with two common RA treatment strategies, triple therapy or tumor necrosis factor inhibitor (TNFi), and association with CV risk.

Methods

In this secondary data analysis of the TARGET trial, methotrexate (MTX) inadequate responders with RA were randomized to either add sulfasalazine and hydroxychloroquine (triple therapy), or TNFi for 24-weeks. The primary trial outcome was the change in arterial inflammation measured in the carotid arteries or aorta by FDG-PET/CT at baseline and 24-weeks; this change was described as the target-to-background ratio (TBR) in the most diseased segment (MDS). Routine lipids and advanced lipoproteins were measured at baseline and 24-weeks; subjects on statin therapy at baseline were excluded. Comparisons between baseline and follow-up lipid measurements were performed within and across treatment arms, as well as change in lipids and change in MDS-TBR.

Results

We studied 122 participants, 61 in each treatment arm, with median age 57 years, 76% female, and 1.5 year median RA disease duration. When comparing treatment arms, triple therapy had on average a larger reduction in triglycerides (15.9 mg/dL, p = 0.01), total cholesterol to HDL-C ratio (0.29, p-value = 0.01), and LDL particle number (111.2, p = 0.02) compared to TNFi. TNFi had on average a larger increase in HDL particle number (1.6umol/L, p = 0.006). We observed no correlation between change in lipid measurements and change in MDS-TBR within and across treatment arms.

Conclusions

Both treatment strategies were associated with improved lipid profiles via changes in different lipids and lipoproteins. These effects had no correlation with change in CV risk as measured by vascular inflammation by FDG-PET/CT.

Trial registration

ClinicalTrials.gov ID NCT02374021.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidAntirheumatic AgentsHydroxychloroquineLipidsDrug Therapy, CombinationMethotrexateHumansFemaleMiddle AgedMaleAgedSulfasalazineAdultTumor Necrosis Factor InhibitorsTreatment OutcomePositron Emission Tomography Computed TomographyVasculitis

Stichwörter der Autor:innen

Cardiovascular diseaseLipidsRheumatoid arthritis

Substanzen

Antirheumatic AgentsHydroxychloroquineLipidsMethotrexateSulfasalazineTumor Necrosis Factor Inhibitors

Autor:innen und Institutionen

  • Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, 60 Fenwood Rd, Boston, MA, 02115, USA. kliao@bwh.harvard.edu.
  • Department of Medicine, Harvard Medical School, Boston, MA, USA. kliao@bwh.harvard.edu.
  • Department of Medicine, Harvard Medical School, Boston, MA, USA.
  • Division of Preventive Medicine, Brigham and Women's Hospital, Boston, MA, USA.
  • Division of Rheumatology, College of Physicians and Surgeons, Columbia University, New York, NY, USA.
  • Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, 60 Fenwood Rd, Boston, MA, 02115, USA.

Förderung

  • NHLBI NIH HHS
  • NIAMS NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Liao, K. P., Rist, P., Giles, J., Santacroce, L., Connelly, M. A., Glynn, R. J., Ridker, P., Tawakol, A., Bathon, J., & Solomon, D. H. (2024). Impact of RA treatment strategies on lipids and vascular inflammation in rheumatoid arthritis: a secondary analysis of the TARGET randomized active comparator trial. Arthritis Research & Therapy. https://doi.org/10.1186/s13075-024-03352-3

Vancouver

Liao KP, Rist P, Giles J, Santacroce L, Connelly MA, Glynn RJ, et al. Impact of RA treatment strategies on lipids and vascular inflammation in rheumatoid arthritis: a secondary analysis of the TARGET randomized active comparator trial. Arthritis Research & Therapy. 2024. doi:10.1186/s13075-024-03352-3

BibTeX
@article{Liao2024,
  author = {Liao, Katherine P and Rist, Pamela and Giles, Jon and Santacroce, Leah and Connelly, Margery A and Glynn, Robert J and Ridker, Paul and Tawakol, Ahmed and Bathon, Joan and Solomon, Daniel H},
  title = {Impact of RA treatment strategies on lipids and vascular inflammation in rheumatoid arthritis: a secondary analysis of the TARGET randomized active comparator trial},
  journal = {Arthritis Research & Therapy},
  year = {2024},
  doi = {10.1186/s13075-024-03352-3}
}
Kostenlos starten →